一分钟看懂
这是一项关于白血病的I 期研究，登记的药物或干预包括Treatment Arm A，当前状态为招募中。登记地点显示中国Houston有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Treatment Arm A · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Texas Children's Hospital · Houston
- The Methodist Hospital · Houston
公开的入选条件
- 1. Diagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML) with the exception of acute promyelocytic leukemia (APL). Patients with targetable mutations should have failed or be ineligible for targeted therapies (e.g. FLT3 inhibitors, IDH inhib
- Patients with other relapsed or refractory CD70+ leukemia that would be considered an indication for allogeneic Hematopoietic Stem Cell Transplant (HSCT) if remission can be achieved. (CD19+ leukemia only: Patients must have failed or be ineligible to receive
- Primary refractory or resistant disease, for purposes of procurement, defined as not achieving complete remission (CR) (i.e., a remaining blast count of 5% or more) after 1 to 2 cycles of intense induction therapy.
- Relapse is defined as (1) hematologic relapse after complete remission based on bone marrow blasts \>=5%, or reappearance of blasts in the blood, or development of extramedullary disease; (2) molecular relapse after minimal residual disease (MRD) negative, com
- 2. CD70 positive leukemia with at least 26% CD70+ blasts by flow cytometry or immunohistochemistry (staining can be pending at time of procurement)
- 3. Age ≤75 years. NOTE: The first three (3) patients treated on the study will be adults (≥18 years of age)
- 4. Hemoglobin ≥ 7.0 g/dL (can be transfused)
- 5. If apheresis required to collect blood
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06345027；登记信息更新于 2026-09-16。